Answers are grounded in this paper and cite their sources.
Purpose : Sepsis and septic shock are life-threatening conditions associated with high mortality rates. CytoSorb is an extracorporeal cytokine adsorption device that has emerged as a potential adjunct therapy. However, its effectiveness remains controversial. To evaluate the effectiveness of CytoSorb hemoadsorption therapy in patients with sepsis and septic shock, we focused on the clinical outcomes and cytokine levels.Methods : A systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The PubMed, Embase, Web of Science, and CINAHL databases were searched from their inception to September 25, 2024. We included randomized controlled trials and observational studies comparing CytoSorb with standard care in adult patients with sepsis or septic shock. The primary outcomes were the 28-day and in-hospital mortality rates. The secondary outcomes included changes in cytokine levels and length of hospital stay.Results : We included 10 studies with 759 patients (517 patients treated with CytoSorb and 242 controls). The meta-analysis of mortality (481 CytoSorb and 335 controls) showed no significant differences between the groups (risk ratio: 0.99, 95% confidence interval [CI]: 0.75 to 1.30, p =0.93). The analysis of length of hospital stay (528 CytoSorb and 246 controls) showed a nonsignificant trend favoring the control group (SMD= 0.06, 95% CI: –0.09 to 0.22, p =0.44) with no heterogeneity (I2 =0%). CytoSorb significantly reduced IL-6 levels (SMD=–0.43, 95% CI: –0.83 to –0.03, p =0.04).Conclusion : Although CytoSorb can reduce cytokine levels, its effects on mortality and other clinical outcomes remain unclear. Several studies have suggested that optimal patient selection and intervention timing are crucial.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: